Advertisement

Topics

Search Results for "Sunitinib"

20:49 EDT 22nd August 2017 | BioPortfolio

Matching Channels

None

Matching News

Individualized Sunitinib Dosing Improves Response, Survival in RCC

Individualizing first-line sunitinib was associated with improved response and survival times among patients with metastatic renal cell carcinoma.

Global and Chinese Sunitinib base Industry, 2017 Market Research Report [Report Updated: 07042017] Prices from USD $3000

The 'Global and Chinese Sunitinib base Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Sunitinib base industry with a focus on the Chi...

Sunitinib Malate Market: By Disease Pancreatic Neuroendocrine Tumors Kidney Cancer By Region Europe, North America, AsiaPacific Rest of the World RoWForecast 20162021 [Updated: 13092016] Prices from USD $5250

Sunitinib, developed and marketed as Sutent by Pfizer Inc and previously known as SU11248, is a smallmolecule medicine which has to be administered orally and has been proven to be effective in blocki...

Bristol-Myers Squibb’s Kidney Cancer Drug Met Co-Primary Endpoint in Late-Stage Trial

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) announced topline results today from the CheckMate -214 trial investigating Opdivo (nivolumab) in combination wi...

Kidney cancer: FBV indicates sunitinib response

Sunitinib induces genomic instability of renal carcinoma cells through affecting the interaction of LC3-II and PARP-1

Human medicines European public assessment report (EPAR): Sutent, sunitinib, Revision: 30, Authorised

Pfizer Announces Acceptance Of Regulatory Submissions By U.S. FDA And EMA For SUTENT (Sunitinib) For Adjuvant Treatment Of Adult Patients At High Risk Of Recurrent Renal Cell Carcinoma After Surgery

  Life Sciences Jobs   ...

Matching PubMed Articles

Diclofenac sex-divergent drug-drug interaction with Sunitinib: pharmacokinetics and tissue distribution in male and female mice.

Coadministration of diclofenac and sunitinib, tyrosine kinase inhibitor, led to sex-divergent pharmacokinetic drug-drug interaction outcomes. Male and female mice were administered 60 mg/kg PO suniti...

Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis.

The most efficient sequence of targeted agents for metastatic renal cell carcinoma patients has yet to be identified. Whether the sequence of sorafenib and sunitinib really matters is controversial an...

Mixed Results for Sunitinib in Renal Cancer.

Two studies presented at the European Society for Medical Oncology 2016 Congress evaluated sunitinib in patients with renal cell carcinomas. The first found that the drug prevents recurrence in patien...

Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives.

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. In advanced setting and after progression to imatinib, the multi-targeted receptor tyrosine ki...

In vitro biologic efficacy of sunitinib drug-eluting beads on human colorectal and hepatocellular carcinoma-A pilot study.

Sunitinib drug eluting beads (DEB) are a novel anti-angiogenic bead preparation for use in transarterial chemoembolization. However, systematic studies of sunitinib DEB's effect on cancer cells have n...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement